×
About 86,808 results

ALLMedicine™ Melanoma Center

Research & Reviews  27,261 results

Margin Size for Unique Skin Tumors Treated With Mohs Micrographic Surgery: A Survey of Practice Patterns
https://www.mdedge.com/dermatology/article/258487/melanoma/margin-size-unique-skin-tumors-treated-mohs-micrographic-surgery
Frances M. Walocko, MD, MEng, Christian Carr, MPH et. al.

Oct 6th, 2022 - Mohs micrographic surgery (MMS) is most commonly used for the surgical management of squamous cell carcinomas (SCCs) and basal cell carcinomas (BCCs) in high-risk locations. The ability for 100% margin evaluation with MMS also has shown lower recu.

Up-Frameshift Suppressor 3 as a prognostic biomarker and correlated with immune infiltr...
https://doi.org/10.1371/journal.pone.0273163
PloS One; Xu J, Ma H et. al.

Oct 5th, 2022 - The mRNA expression of protein Up-Frameshift Suppressor 3 Homolog B (UPF3B) differ in different tumors. However, the clinical relevance of UPF3B in cancer patients, such as with prognosis, tumor stage, and levels of tumor-infiltrating immune cells...

Sinonasal mucosal melanomas: defining profiles for better survival outcomes.
https://doi.org/10.4193/Rhin21.251
Rhinology Rojas-Lechuga MJ, Gras-Cabrerizo JR et. al.

Oct 4th, 2022 - Sinonasal mucosal melanoma is an aggressive malignancy with a 5-year survival rate ranging from 20% to 39%. Despite the evolving surgical and radiotherapy techniques, and introduction of immune-checkpoint inhibitor therapy, overall survival rates ...

Genomic profiling with whole-exome sequencing revealed distinct mutations and novel pat...
https://doi.org/10.1111/1346-8138.16579
The Journal of Dermatology; Chiu YJ, Weng HY et. al.

Oct 4th, 2022 - The clinical characteristics of malignant melanoma are highly variable between patient populations of different ethnicities. To explore the underlining genetic variations, we reviewed the clinical data of 242 malignant melanoma cases from Taiwan a...

Cutaneous Melanoma: Sheep in Wolves Clothing?
https://doi.org/10.21873/anticanres.16010
Anticancer Research; DE Gruijl FR, Armstrong BK

Oct 4th, 2022 - Cutaneous melanoma incidence in European-origin populations has risen steeply, however, mortality has not, as 73 years of Danish cancer data strikingly show. It has been suggested that such divergent trends in the US are due to overdiagnosis from ...

see more →

Guidelines  43 results

Fish intake and risk of melanoma in the NIH-AARP diet and health study
https://link.springer.com/article/10.1007/s10552-022-01588-5
Cancer Causes Control; Li, Y. et. al.

Jun 9th, 2022 - Prior epidemiological studies evaluating the association between fish intake and melanoma risk have been few and inconsistent. Few studies distinguished different types of fish intake with risk of melanoma.

Higher fish consumption associated with increased melanoma risk, study suggests
https://www.brown.edu/news/2022-06-09/fish-melanoma
News from Brown University;

Jun 9th, 2022 - A new analysis from a Brown University team shows a connection between eating fish and developing skin cancer, and the researchers say bio-contaminants like mercury are a likely cause.

European consensus-based interdisciplinary guideline for melanoma. Part 2: Treatment - ...
https://doi.org/10.1016/j.ejca.2022.04.018
European Journal of Cancer (Oxford, England : 1990); Garbe C, Amaral T et. al.

May 28th, 2022 - A unique collaboration of multidisciplinary experts from the European Dermatology Forum (EDF), the European Association of Dermato-Oncology (EADO), and the European Organization of Research and Treatment of Cancer (EORTC) was formed to make recomm...

Clinical features, molecular characteristics and surgical management of primary penile ...
https://doi.org/10.1097/CMR.0000000000000788
Melanoma Research; Cakir OO, Pozzi E et. al.

Nov 30th, 2021 - Penile mucosal melanoma is an aggressive and rare genital malignancy. The aim of the present study was to review the management and outcomes of a homogenous cohort of patients with histologically confirmed penile mucosal melanoma, at a single spec...

New Eye Cancer Therapy Shown to Target Cancer Cells, Spare Vision
https://www.aao.org/newsroom/news-releases/detail/new-eye-cancer-therapy-shown-to-target-cancer-cell
American Academy of Ophthalmology

Nov 15th, 2021 - NEW ORLEANS, La. – Choroidal melanoma is a rare cancer that affects the back of the eye. If the tumor grows, it can cause the retina to detach, leading to vison loss. And if it spreads to other parts of the body, it can be fatal. There are no appr...

see more →

Drugs  64 results see all →

Clinicaltrials.gov  2,958 results

Non-Viral TCR Gene Therapy
https://clinicaltrials.gov/ct2/show/NCT04102436

Sep 30th, 2022 - Background: The administration of autologous tumor infiltrating lymphocytes (TIL) can mediate complete, durable regressions in 20-25% of patients with metastatic melanoma. Recent studies have shown that these TIL predominantly recognize unique mut...

Palbociclib and Binimetinib in RAS-Mutant Cancers, A ComboMATCH Treatment Trial
https://clinicaltrials.gov/ct2/show/NCT05554367

Sep 30th, 2022 - PRIMARY OBJECTIVES: I. To determine whether palbociclib and binimetinib combination therapy improves progression free survival (PFS) compared to binimetinib alone in patients with MEK-inhibitor naive low-grade serous ovarian cancer (LGSOC) harbori...

Neoadjuvant/Adjuvant Sintilimab, Nab-paclitaxel, and Gemcitabine for Resectable/Borderline Resectable Pancreatic Cancer
https://clinicaltrials.gov/ct2/show/NCT05562297

Sep 30th, 2022 - Pancreatic cancer is a highly fatal disease with a 5-year survival rate of less than 5%, and it is becoming an increasingly common cause of cancer mortality. Neoadjuvant therapy, such as gemcitabine plus nab-paclitaxel, can effectively avoid the p...

A Study of ONCOS-102 in Combination With Other Novel Immune-therapies in Advanced Treatment-resistant Melanoma Patients
https://clinicaltrials.gov/ct2/show/NCT05561491

Sep 30th, 2022 - This study will test ONCOS-102 in combination with novel immune-targeted anti-cancer agents in patients with unresectable or metastatic cutaneous melanoma resistant to anti-PD (L)1 treatment. The purpose of this study is to further evaluate safety...

Clinical Study of Fianlimab in Combination With Cemiplimab in Adolescent and Adult Patients With Previously Untreated Unresectable Locally Advanced or Metastatic Melanoma
https://clinicaltrials.gov/ct2/show/NCT05352672

Sep 30th, 2022 - The primary objective of the study is to demonstrate superiority of fianlimab + cemiplimab compared to pembrolizumab, as measured by progression-free survival (PFS) The secondary objectives of the study are: To demonstrate superiority of fianlimab...

see more →

News  4,357 results

Margin Size for Unique Skin Tumors Treated With Mohs Micrographic Surgery: A Survey of Practice Patterns
https://www.mdedge.com/dermatology/article/258487/melanoma/margin-size-unique-skin-tumors-treated-mohs-micrographic-surgery
Frances M. Walocko, MD, MEng, Christian Carr, MPH et. al.

Oct 6th, 2022 - Mohs micrographic surgery (MMS) is most commonly used for the surgical management of squamous cell carcinomas (SCCs) and basal cell carcinomas (BCCs) in high-risk locations. The ability for 100% margin evaluation with MMS also has shown lower recu.

Image-Guided Superficial Radiation as First-line in Skin Cancer?
https://www.medscape.com/viewarticle/981722

Sep 30th, 2022 - The study covered in this summary was published on medRxiv.org as a preprint and has not yet been peer reviewed. Key Takeaway Absolute lesion control rate with image-guided superficial radiation therapy (IGSRT) for early-stage non-melanoma skin ca...

In stage IIIA melanoma, nodal tumor size could guide decision-making
https://www.mdedge.com/hematology-oncology/article/258242/melanoma/stage-iiia-melanoma-nodal-tumor-size-could-guide
Jim Kling

Sep 27th, 2022 - Among patients with American Joint Committee on Cancer IIIA early-stage melanoma metastases, the presence of sentinel node (SN) tumor deposits of 0. 3 mm or higher is associated with a greater risk of disease progression, and these individuals may.

Despite Benefits, Extended-Interval Pembro Uptake Remains Low
https://www.medscape.com/viewarticle/981498

Sep 27th, 2022 - Uptake of the approved extended-interval dosing regimen for pembrolizumab has been poor, according to a review of Veterans Health Administration data. In April 2020, the US Food and Drug Administration (FDA) approved extended dosing for stand-alon...

In Stage IIIA Melanoma, Nodal Tumor Size Could Guide Decision-Making
https://www.medscape.com/viewarticle/981505

Sep 27th, 2022 - Among patients with American Joint Committee on Cancer IIIA early-stage melanoma metastases, the presence of sentinel node (SN) tumor deposits of 0.3 mm or higher is associated with a greater risk of disease progression, and these individuals may ...

see more →

Patient Education  40 results see all →